Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM01 subcutaneous once-weekly versus three-times-weekly in anaemia of chronic renal failure
2005-000144-87Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin theta in anemia of chronic kidney disease (2 arms), sponsored by BioGeneriX AG. Primary endpoints: Therapeutic equivalence in haemoglobin control and Mean weekly dose equivalence. Started Sep 2005; status: completed.
02
Drugs
epoetin theta
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2005-000144-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000144-87.